AZADYNE

azadyne-logo

Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in Biochemistry Vincent Kelly, Professor of Synthetic Chemistry Professor Stephen Connon and assistant Professor in Chemistry John Michael Southern.

#SimilarOrganizations #People #Financial #Website #More

AZADYNE

Social Links:

Industry:
Health Care

Founded:
2016-01-01

Address:
Dublin, Dublin, Ireland

Country:
Ireland

Website Url:
http://www.azadyne.com

Total Employee:
1+

Status:
Active

Total Funding:
1.75 M EUR

Technology used in webpage:
Pound Sterling Gravity Forms


Similar Organizations

cabaletta-bio-logo

Cabaletta Bio

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

not_available_image

D2M Biotherapeutics

D2M Biotherapeutics focuses on the development of novel immunotherapeutics.

elgia-therapeutics-logo

Elgia Therapeutics

Elgia Therapeutics is a biopharmaceutical company.

kytopen-logo

Kytopen

Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.

metis-therapeutics-logo

METiS Therapeutics

METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.

recensa-therapeutics-logo

Recensa Therapeutics

Recensa Therapeutics, Inc. has a new approach to treating psoriasis: targeting oxidative stress.

stipe-therapeutics-logo

STipe Therapeutics

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.

Current Employees Featured

jason-rutt_image

Jason Rutt
Jason Rutt CEO @ Azadyne
CEO
2017-11-01

Founder


jason-rutt_image

Jason Rutt

Investors List

renaissance-capital-partners_image

Renaissance Capital Partners

Renaissance Capital Partners investment in Venture Round - Azadyne

ncl_image

NCL Technology Ventures

NCL Technology Ventures investment in Seed Round - Azadyne

renaissance-capital-partners_image

Renaissance Capital Partners

Renaissance Capital Partners investment in Seed Round - Azadyne

Official Site Inspections

http://www.azadyne.com Semrush global rank: 11.54 M Semrush visits lastest month: 156

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Azadyne"

New approach to treating autoimmune disease - Azadyne

Azadyne Azadyne are a preclinical biotech company with a new approach to treating autoimmune disease. We have identified a new target within the body and a previously undrugged pathway. …See details»

About Us - Azadyne

Azadyne’s groundbreaking work in RNA modification has been supported by investment syndicates led by NCL & Kent Life Sciences and private equity group 24 Haymarket. Azadyne is a virtual company with a team of experienced …See details»

Azadyne - Crunchbase Company Profile & Funding

Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in …See details»

Azadyne Ltd - LinkedIn

Azadyne Ltd | 234 followers on LinkedIn. Treating Autoimmune disease. | We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including ...See details»

Azadyne 2025 Company Profile: Valuation, Funding & Investors

Azadyne General Information Description. Developer of novel RNA modification technologies designed to treat autoimmune diseases by increasing treg cell levels. The company aims to …See details»

Azadyne - Headquarter Location, Corporate Office Address and …

Azadyne is Biotechnology business from United Kingdom that founded in 2018 (7 years old in 2025), Azadyne business is focusing on Developer. Where is Azadyne headquarter and …See details»

Azadyne Company Profile - Office Locations, Competitors ... - Craft

Azadyne is a pharmaceutical research and development company. It is engaged in discovering medicines for patients with autoimmune disease, including multiple sclerosis.See details»

Azadyne Announce Funding Round

Azadyne’s proprietary and innovative approach to autoimmune disease via the tRNA guanine transglycosylase (TGT) enzyme pathway has shown striking efficacy in pre-clinical studies …See details»

Azadyne - VentureRadar

Azadyne was founded based on published research findings, showing that queuine mimetics can drastically reverse the clinical disease process (i.e. paralysis and autoimmunity) associated …See details»

Azadyne - Funding, Financials, Valuation & Investors - Crunchbase

Azadyne is a new approach to the treatment of autoimmune diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much funding has …See details»

AZADYNE LTD Company Profile | LONDON, United Kingdom

Find company research, competitor information, contact details & financial data for AZADYNE LTD of LONDON. Get the latest business insights from Dun & Bradstreet. D&B Business …See details»

Azadyne – Funding, Valuation, Investors, News

Sep 30, 2022 We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including Multiple Sclerosis. AZADYNE originated from …See details»

Azadyne - Products, Competitors, Financials, Employees, …

Azadyne operates as a preclinical biotechnology company focused on the healthcare sector, specifically in the field of autoimmune disease treatment. The company's main service …See details»

Azadyne - Contacts, Employees, Board Members, Advisors & Alumni

Azadyne is a new approach to the treatment of autoimmune diseases. AI Content may contain mistakes and is not legal, financial or investment advice.See details»

Science & Pipeline - Azadyne

Azadyne’s research has focused on the exploitation of the queuine tRNA ribosyltransferase (QTRT) enzyme pathway (also known as TGT), characterised by the founders (Boland et al., …See details»

Azadyne - EU-Startups

Azadyne is a biotech spin-out company from Trinity College Dublin founded by Professors Stephen Connon, Vincent Kelly, Mike Southern and CEO, Dr. Jason Rutt, ex head of UK …See details»

Contact - Azadyne

Azadyne is always keen to discuss its science. To learn more about the work we are doing, or to discuss ways we can work together, please get in contact using the form below. Name …See details»

Azadyne, a biotech startup targeting autoimmune disease wins …

Cambridge, UK, November 2nd, 2022: o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition.Azadyne’s approach has shown striking efficacy in …See details»

Azadyne, a biotech startup targeting autoimmune disease wins …

O2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine …See details»

News - Azadyne

Read More about Azadyne speaking at FASEB RNA conference. March 27, 2019 Azadyne Announce Funding Round. Azadyne, which is developing a new approach to the treatment of …See details»

linkstock.net © 2022. All rights reserved